Interferon-free therapy for hepatitis C: The hurdles amid a golden era

Digestive and Liver Disease

Volumn 47, Issue 9, 2015, Pages 727-733

  Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Daclatasvir; Hepatitis C; Interferon; Simeprevir; Sofosbuvir

Indexed keywords

DACLATASVIR; DASABUVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; ABT-333; ANTIVIRUS AGENT; SULFONAMIDE; URACIL;

ANTIVIRAL THERAPY; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; GENOTYPE; HEPATITIS C; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; REINFECTION; REVIEW; TREATMENT INDICATION; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; EMBRYOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDES; TREATMENT OUTCOME; URACIL;

EID: 84939255713     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.04.003     Document Type: Review

References (44)

1. European Medicines Agency (EMA). Sovaldi registration details. [accessed 06.02.15]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002798/human_med_001723.jsp%26mid=WC0b01ac058001d124.
2. U.S. Food and Drug Administration (FDA). Sovaldi registration details. DrugDetails [accessed 12.02.15]. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.
3. European Medicines Agency (EMA). Harvoni registration details. [accessed 06.02.15]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003850/human_med_001813.jsp%26mid=WC0b01ac058001d124.
4. U.S. Food and Drug Administration (FDA). Harvoni registration details. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
5. European Medicines Agency (EMA). Daklinza registration details. [accessed 06.02.15]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003768/human_med_001792.jsp%26mid=WC0b01ac058001d124.
6. European Medicines Agency (EMA). Olysio registration details. [accessed 06.02.15]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002777/human_med_001766.jsp%26mid=WC0b01ac058001d124.
7. U.S. Food and Drug Administration (FDA). Olysio registration details. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
8. U.S. Food and Drug Administration (FDA). Viekirax®+Exviera registration details. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
9. EpaC Onlus newsletter at http://www.epac.it/.
10. Associazione Italiana per lo Studio del Fegato (AISF). Libro Bianco AISF 2011: Proposta per un piano Nazionale delle malattie epatiche. [accessed 05.02.15]. http://www.webaisf.org/media/13891/libro-bianco-aisf-2011.pdf.
11. Leidner A.J., Chesson H.W., Xu F., et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015, [in press].
12. Agenzia Italiana del Farmaco (AIFA). Sovaldi prescription criteria in Italy. [accessed 06.02.15]. http://www.agenziafarmaco.gov.it/sites/default/files/SOVALDI_Scheda_AIFA_10.12.2014.pdf.
13. Jensen D.M., O'Leary J.G., Pockros P.J., et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Hepatology 2014, 60(Suppl.):219A-220A.
14. Dieterich D., Bacon B.R., Flamm S.L., et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014, 60(Suppl.):220A.
15. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 2014, 370:211-221.
16. Bourliere M., Bronowicki J., De Ledinghen V., et al. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease inhibitor based triple therapy. Hepatology 2014, 60(Suppl.). LB-6.
17. Afdhal N., Everson G., Calleja J.L., et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. Journal of Hepatology 2014, 60(Suppl.):S28.
18. Flamm S.L., Everson G.T., Charlton M., et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014, 60(Suppl.):320A.
19. Zeuzem S., Dusheiko G.M., Salupere R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. New England Journal of Medicine 2014, 370:1993-2001.
20. Pianko S., Flamm S.L., Shiffman M.L., et al. High efficacy of treatment with sofosbuvir+GS-5816±ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection. Hepatology 2014, 60(Suppl.):297A-298A.
21. Ruane P.J., Ain D., Meshrekey R., et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. Journal of Hepatology 2014, 60(Suppl.):S503-S504.
22. Kapoor R., Kohli A., Sidharthan S., et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology 2014, 60(Suppl.):321A.
23. Hassanein T., Sims K.D., Bennett M., et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. Journal of Hepatology 2015, 62:1204-1206.
24. Curry M.P., Forns X., Chung R.T., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015, 148:100-107.
25. Charlton M., Gane E., Manns M.P., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015, 148:108-117.
26. Pellicelli A.M., Montalbano M., Lionetti R., et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Digestive and Liver Disease 2014, 46:923-927.
27. Reddy K.R., Everson G.T., Flamm S.L., et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 2014, 60(Suppl.):200A-201A.
28. Donato M.F., Monico S., Malinverno F., et al. Bridging all-oral DAA therapy from wait time to post-liver transplant to improve HCV eradication. Liver International 2015, 35:1-4.
29. Chang K.C., Hung C.H., Lu S.N., et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. Journal of Antimicrobial Chemotherapy 2012, 67:2766-2772.
30. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012, 56:908-943.
31. Bruno S., Crosignani A., Maisonneuve P., et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007, 46:1350-1356.
32. van der Meer A.J., Veldt B.J., Feld J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Journal of the American Medical Association 2012, 308:2584-2589.
33. Lee M.H., Yang H.I., Lu S.N., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. Journal of Infectious Diseases 2012, 206:469-477.
34. Hill A.M., Saleem J., Heath K.A., et al. Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with hepatitis C infection. Hepatology 2014, 60(Suppl.):218A-219A.
35. Jepsen P., Vilstrup H., Lash T.L. Development and validation of a comorbidity scoring system for patients with cirrhosis. Gastroenterology 2014, 146:147-156.
36. McCombs J., Matsuda T., Tonnu-Mihara I., et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Internal Medicine 2014, 174:204-212.
37. Akuta N., Suzuki F., Hirakawa M., et al. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. Journal of Medical Virology 2011, 83:1016-1022.
38. Arase Y., Suzuki F., Suzuki Y., et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009, 49:739-744.
39. Hsu Y.C., Lin J.T., Ho H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014, 59:1293-1302.
40. Kohli A., Sims Z., Marti M., et al. Combination oral, ribavirin free, antiviral therapy to optimize treatment outcomes for hepatitis C GT-1 treatment naïve patients: interim results from the NIAID SYNERGY trial. Hepatology 2013, 58(Suppl.):1382A.
41. Kowdley K.V., Gordon S.C., Reddy K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine 2014, 370:1879-1888.
42. Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. New England Journal of Medicine 2013, 368:34-44.
43. Lawitz E., Poordad F., Gutierrez J.A., et al. C-SWIFT: MK-5172+MK-8742+sofosbuvir in treatment naïve patients with hepatitis C virus genotype 1 infection, with and without cirrhosis. Hepatology 2014, 60(Suppl.). LB-33.
44. Gane E.J., Hyland R.H., An D.A., et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology 2014, 60(Suppl.). LB-11.